|
Baseline laboratory findings
|
|
Total leukocytes (N cells/mm3, median (IQR))
|
7.0 (4.5–9.1)
|
|
Total lymphocytes (N cells/mm3, median (IQR))
|
0.9 (0.5–1.4)
|
|
CD19 positive cells (n = 37) (N cells/mm3/percentage median (IQR))
|
0.05 (0.03–0.12)/7.0 (4.0–13.0)
|
|
Anti-dsDNA positivity, (n, %)
|
44 (66.7)
|
|
Low complement levels (n = 61), (n, %)
|
35 (57.4)
|
|
Primary indication for RTX
|
|
Lupus nephritis, n (%)
|
42 (63.6)
|
|
Neurolupus, n (%)
|
7 (10.6)
|
|
Lupus related arthritis, n (%)
|
7 (10.6)
|
|
Mucocutaneous manifestations, n (%)
|
2 (3.0)
|
|
Haematological manifestations, n (%)
|
5 (7.6)
|
|
Other manifestationsa, n (%)
|
3 (4.5)
|
|
Ongoing treatment at RTX initiation
|
|
Oral Prednisolone, n (%)
|
61 (92.4),
|
|
Daily dose, mg (median (IQR))
|
12.5 (12.5–20.0)
|
|
Antimalarials, n (%)
|
27 (40.9)
|
|
Azathioprine, n (%)
|
6 (9.1)
|
|
Mycophenolate, n (%)
|
9 (13.6)
|
|
Methotrexate, n (%)
|
3 (4.5)
|
|
Previous treatments
|
|
Cyclophosphamide, n (%)
|
40 (60.6)
|
|
Cumulative dose (median (IQR))
|
6075 (3150–9275)
|
|
Azathioprine, n (%)
|
44 (66.7)
|
|
Mycophenolate, n (%)
|
32 (48.5)
|
|
Methotrexate, n (%)
|
17 (25.8)
|
|
Cyclosporine A, n (%)
|
11 (16.7)
|
